DEFA14A: Dynavax Defends Strategy Against Deep Track, Highlights Stockholder Value and Pipeline Potential

Dynavax Technologies Corporation is urging stockholders to vote for its board nominees, highlighting its successful transformation into a commercial-stage vaccine company and defending its strategy against a challenge from Deep Track Capital.

Summary

• Dynavax is soliciting proxies for its 2025 Annual Meeting of Stockholders.
• The company emphasizes its successful pivot from immuno-oncology to a commercial vaccine business, particularly with HEPLISAV-B.
• Dynavax highlights its strong financial performance, including a 203% total return to stockholders over the last five years, compared to a 9% return for vaccine peers and a 17% decline for the S&P Biotechnology Select Industry Index.
• HEPLISAV-B achieved $268 million in revenue in 2024 and holds a 44% U.S. market share.
• The company generated over $950 million in net product revenue from 2020 to 2022 through CpG 1018 adjuvant commercial supply agreements for COVID-19 vaccines.
• Dynavax ended 2024 with a cash balance of $714 million and has returned capital to stockholders.
• The company is progressing a clinical vaccine pipeline, including a Phase 2 shingles vaccine candidate and a plague vaccine program in partnership with the U.S. DoD.
• Dynavax aims to achieve at least 60% total U.S. market share for HEPLISAV-B by 2030.
• The document criticizes Deep Track's plan to immediately return all available cash to stockholders and abandon portfolio diversification, arguing it would jeopardize long-term growth.
• Dynavax claims to have made multiple settlement proposals to Deep Track, all of which were rejected.
• The company defends its board refreshment process and the skills and experience of its directors.
• Dynavax argues that Deep Track is distorting facts about the company's performance and strategic pivot.
• The company is urging stockholders to vote for its board nominees.

Sentiment

Score: 7

Explanation: The document presents a positive view of Dynavax's performance and future prospects, while also addressing the challenges posed by the proxy contest. The tone is confident and defensive, aiming to persuade stockholders to support the current management and board.

Positives

• Dynavax has successfully pivoted to a commercial-stage vaccine company.
• HEPLISAV-B is now the market-leading hepatitis B vaccine.
• The company has a promising clinical vaccine pipeline.
• Dynavax has a strong cash position and has returned capital to stockholders.
• The company has a clear strategy for growth and value creation.
• Analysts have confidence in management's ability to execute.
• The company has a diversified commercial portfolio and robust pipeline.
• Dynavax has a low-cost capital structure and efficient capital allocation.
• The company has a superior technology and a fully integrated platform.
• The company has a proactive and diverse board.

Negatives

• Dynavax is facing a proxy contest from Deep Track Capital.
• Deep Track's plan could jeopardize the company's long-term growth prospects.
• The company is being criticized for its capital allocation strategy.
• Deep Track is distorting facts about the company's performance.
• The company is being accused of empire-building acquisitions.
• The company is being accused of not negotiating in good faith with Deep Track.

Risks

• The proxy contest with Deep Track could be distracting and costly.
• Deep Track's plan could negatively impact the company's stock price.
• The company's pipeline candidates may not be successful.
• The company may not be able to achieve its market share goals for HEPLISAV-B.
• The company may not be able to find attractive acquisition targets.
• The company's business could be affected by competition and regulatory changes.
• The company's business could be affected by challenging macro environment.

Future Outlook

Dynavax expects double-digit CAGR for HEPLISAV-B net product sales through 2030 and aims to achieve at least 60% total U.S. market share by 2030. The company plans to advance its differentiated vaccine pipeline and identify strategic opportunities to accelerate growth.

Management Comments

• Management and the Board transformed Dynavax from a struggling biotech company into a powerful commercial-stage vaccine company.
• Deep Track is trying to make us a victim of our own success.
• We are executing a clear strategy that is generating record results and delivering strong returns for stockholders.

Industry Context

The document positions Dynavax as a successful player in the vaccine market, highlighting its ability to compete with established legacy products and its potential to disrupt large markets like shingles. It also addresses the competitive landscape and the importance of long-term platform diversification.

Comparison to Industry Standards

• Dynavax's HEPLISAV-B has overtaken GSK's ENGERIX-B vaccine as the market leader.
• HEPLISAV-B offers 95%+ protection after 1 month compared to 81% for ENGERIX-B.
• Dynavax's stock has returned +203% TSR over the last five years vs. S&P Biotechnology Select Industry Index (XBI) -17% and Vaccine Peer Median +9%.
• The company compares itself to vaccine peers such as Bavarian Nordic, Emergent BioSolutions, Novavax, Valneva, and Vaxcyte.

Corporate Governance

Stakeholder Impact

• Shareholders: The document aims to persuade shareholders to vote for the current board and strategy, promising continued value creation.
• Employees: The document highlights the company's success and growth potential, which could positively impact employee morale and job security.
• Customers: The document emphasizes the benefits of Dynavax's vaccines, particularly HEPLISAV-B, to protect against infectious diseases.
• Suppliers: The document suggests continued business opportunities for suppliers as Dynavax grows and expands its pipeline.
• Creditors: The document highlights the company's strong financial position, which could reassure creditors about the company's ability to meet its obligations.

Next Steps

• Stockholders are urged to vote on the GOLD proxy card for Dynavax's board nominees.
• The company will hold its 2025 Annual Meeting of Stockholders.
• The company will continue to drive growth in HEPLISAV-B.
• The company will advance its differentiated vaccine pipeline.
• The company will identify strategic opportunities to accelerate growth.
• The company will opportunistically return capital to stockholders.

Key Dates

Keywords

Dynavax, HEPLISAV-B, vaccine, Deep Track, proxy, stockholders, board, CpG 1018, pipeline, capital allocation